{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-029660","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.776828+00:00","generated_at":"2026-06-09T01:41:30.823277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics Q3 total net revenue $165.8M; BRIUMVI net sales $25.1M, net income $113.9M","bullets":["BRIUMVI net sales $25.1M in Q3; ~$48.9M cumulative since launch; ~2,200 prescriptions from 500+ providers.","License revenue $140.0M from Neuraxpharm upfront for ex-U.S. commercialization of BRIUMVI in RMS.","Net income $113.9M vs net loss $35.8M YoY; cash position $229.2M as of Sept 30, 2023.","Payor coverage for ~95% of covered lives; permanent J-Code (J2329) effective July 1, 2023.","Company expects existing cash plus BRIUMVI revenues to fund operations into cash flow positivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-029660","json":"https://secwatch.observer/filing/0001437749-23-029660.json","markdown":"https://secwatch.observer/filing/0001437749-23-029660.md","text":"https://secwatch.observer/filing/0001437749-23-029660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/0001437749-23-029660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/tgtx20231030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:41:30.823277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08cb8759f6d753fc1e11b242d5b20dadf83e5a93","claim":"TG THERAPEUTICS, INC. reported three and nine months ended September 30, 2023 results: revenue $165.8 million, net income $113.9 million and $27.1 million.","evidence_excerpt":"Third quarter 2023 total net revenue of $165.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/0001437749-23-029660-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$165.8 million"},{"label":"Net income","value":"$113.9 million and $27.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}